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M A J O R A R T I C L E
Proportion of Pelvic Inﬂammatory Disease Cases Caused
by Chlamydia trachomatis: Consistent Picture From
Different Methods
Malcolm J. Price,1 A. E. Ades,2 Nicky J. Welton,2 Ian Simms,4 John Macleod,2 and Paddy J. Horner2,3
1Institute of Applied Health Research, University of Birmingham, 2School of Social and Community Medicine, University of Bristol, 3Public Health England, London, and 4Bristol Sexual Health Centre,
University Hospital Bristol NHS Foundation Trust, United Kingdom
Background. Pelvic inﬂammatory disease (PID) is a leading cause of both tubal factor infertility and ectopic pregnancy. Chla-
mydia trachomatis is an important risk factor for PID, but the proportion of PID cases caused by C. trachomatis is unclear. Estimates
of this are required to evaluate control measures.
Methods. We consider 5 separate methods of estimating age-group-speciﬁc population excess fractions (PEFs) of PID due to
C. trachomatis, using routine data, surveys, case-control studies, and randomized controlled trials, and apply these to data from the
United Kingdom before introduction of the National Chlamydia Screening Programme.
Results. As they are informed by randomized comparisons and national exposure and outcome estimates, our preferred esti-
mates of the proportion of PID cases caused by C. trachomatis are 35% (95% credible interval [CrI], 11%–69%) in women aged
16–24 years and 20% (95% CrI, 6%–38%) in women aged 16–44 years in the United Kingdom. There is a fair degree of consistency
between adjusted estimates of PEF, but all have wide 95% CrIs. The PEF decreases from 53.5% (95% CrI, 15.6%–100%) in women
aged 16–19 years to 11.5% (95% CrI, 3.0%–25.7%) in women aged 35–44 years.
Conclusions. The PEFs of PID due to C. trachomatis decline steeply with age by a factor of around 5-fold between younger and
older women. Further studies of the etiology of PID in different age groups are required.
Keywords. Chlamydia trachomatis; pelvic inﬂammatory disease; population attributable fraction; population excess fraction;
meta-analysis; Bayesian; evidence synthesis.
Pelvic inﬂammatory disease (PID) is a leading cause of both tubal
factor infertility (TFI) and ectopic pregnancy [1, 2]. PID is a clin-
ical diagnosis typically indicated by lower abdominal pain with
local tenderness on bimanual examination [3]. There are around
50–75 000 PID cases diagnosed in England annually, around one
third of which are in women aged 16–24 years [4]. An unknown
proportion—perhaps as much as 70%—of incident PID cases re-
main undiagnosed [3, 5].Chlamydia trachomatis is an important
risk factor for the development of PID. But PID is also caused by
other infections of the female reproductive tract [6]. With the
many different causes of PID, the extent of the role of C. tracho-
matis in the etiology of PID is unclear.
While the importance of C. trachomatis in the etiology of PID is
widely accepted, attempts to quantify this are limited. Based on 19
studies reporting C. trachomatis prevalence in women with PID
from 1977 to 1992, Paavonen et al [7] reported that C. trachomatis
was involved in 30% of PID cases. Simms and Stephenson [8]
summarized studies of C. trachomatis prevalence in women with
laparoscopically proven PID. The proportion with evidence of cur-
rent C. trachomatis in upper genital tract samples varied from 12%
to 61%, reﬂecting large variation over time and place. However,
these studies lacked a control group, and results depended mark-
edly on the sites from which samples were taken.
In this article, we describe 5 separate although not completely
independent methods to estimate the population excess fraction
(PEF) of PID due to C. trachomatis. The PEF is the most com-
monly used form of population attributable risk fraction and is de-
ﬁned as the proportional reduction in disease risk that would be
achieved by eliminating the exposure of interest from the popula-
tion, assuming the exposure is causally related to the disease [9].
PEF is a property not only of the disease and the exposure, but also
of the time and place where the datawere collected.When estimat-
ing the PEF for a given setting, there are a variety of data sources
with which a credible estimate should be consistent. For example,
the ratio of the incidence of PID to the incidence of C. trachomatis
infection must be the same as the ratio of the risk of PID from
C. trachomatis to the proportion of PID episodes caused by
C. trachomatis. As such, estimates of any 3 of these quantities can
be used to calculate the fourth, and for independent estimates of all
4 to be coherent they must be consistent subject to this constraint.
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We apply the methods to United Kingdom data to develop es-
timates for the period immediately before the onset of the Nation-
al Chlamydia Screening Programme, in 2003 [10]. It has generally
been overlooked that, while both C. trachomatis infection and PID
share the same downward trend in incidence with age, the decline
for C. trachomatis infection is far steeper and occurs at younger
ages [4].There are several plausible explanations for this. The pro-
portion of PID cases diagnosed may increase with age, the risk
that C. trachomatis causes PID may be higher in older women,
or the proportion of PID episodes caused by C. trachomatis
may decline with age [4]. Therefore, age is an important covariate
to consider, especially as it is used to deﬁne the target population
for C. trachomatis screening.
We consider each of the 5 methods in turn. In each case, we re-
view the literature to identify relevant data sources to estimate the
model parameters, performing evidence synthesis where appropri-
ate. We describe the mathematical relationship between the PEF
and the parameters that the data sources estimate. A Bayesian ap-
proach is adopted to ensure correct propagation of uncertainty
from all evidence sources. Finally, we review the various estimates
of PEF and consider the strengths and weaknesses of each method.
METHODS
We brieﬂy describe the 5 methods for estimating the PEF, in turn.
Eachmethod shows how a certain type of data can be used. In each
case, we set out the relevant data sources for the United Kingdom
and any statistical models used to analyze them, and we derive the
joint functional relationships between the parameters they provide
estimates of and the PEF.
PEF Estimate 1 (PEF-1): Crude Estimate From Case-Control Studies and
Age-Speciﬁc C. trachomatis Infection Prevalence Estimates
Case-control studies are commonly used to estimate PEFs. The
standard formula for estimating the PEF from case-control
data [9] is
PEF =
p:ðOR  1Þ
p:ðOR  1Þ þ 1 ;
where OR is the odds ratio (assumed to approximate the inci-
dence rate ratio) of the disease in the exposed group relative to
that in the unexposed groups and π is the prevalence of the ex-
posure in the population of interest. The formula is only correct
when there are no confounding factors or when all confounders
have been adjusted for in the estimation of the odds ratio. The
impact of confounding in observational studies of C. trachomatis
and PID is likely to be signiﬁcant as the risk factors for C. tracho-
matis infection are similar to the risk factors for many other caus-
es of PID (eg, other sexually transmitted infections [STIs]).
Numerous case-control studies comparing measures of C. tra-
chomatis exposure in women with and those without PID have
been published. We only consider case-control studies that
use current infection as a marker of exposure as the risk of
confounding is lower than in studies using measures of cumulative
exposure, such as serological data [4]. Furthermore, we only con-
sider European studies, because the epidemiology of STIs is gen-
erally similar in Western European countries, and we exclude
those published before the 1990s.
Our search identiﬁed 3 studies (Table 1) [11–13], none of
which stratiﬁed by age group or reported sufﬁcient data to attempt
to adjust for confounders. The studies were pooled using a ﬁxed-
effect logistic regression model to obtain a pooled estimate of the
OR. Further details of the search strategy and statistical methods
are provided in Appendix 1.
Estimates of the prevalence of C. trachomatis infection in
women in England by age group are available from a recent syn-
thesis of evidence from prevalence, incidence, and duration stud-
ies [14] (Table 2). The ﬁrst PEF estimate is calculated as follows:
PEFð1Þa ¼
pa:ðORa  1Þ
pa:ðORa  1Þ þ 1 :
Age groups 16–19, 20–24, 25–34, and 35–44 years are indexed by
a. Owing to case-control studies reporting insufﬁcient informa-
tion, the formula assumes that the OR is constant across age strata
(see “Discussion” section).
PEF-2: Estimate From Case-Control Studies Adjusted for Ascertainment
Error and Age-Speciﬁc Prevalence of C. trachomatis Infection
Estimates of the prevalence of C. trachomatis infection in women
with PID differ markedly depending on the sites fromwhich sam-
ples are collected. The 3 studies [11–13] identiﬁed above used
samples from the lower genital tract. However, the presence of
C. trachomatis in the upper genital tract, which is more likely to
be causally related to PID, may not be well predicted by its pres-
ence in the lower genital tract [15, 16]. A recent study in Erfurt,
Table 1. Data and Crude Odds Ratios (ORs) From Retrospective Studies
Used in Population Excess Fraction Estimates 1 and 2
Study, Group Dataa
Crude C. trachomatis
Prevalence (95% CI)
Crude OR
(95% CI)
Paavonen et al [12]
Cases 13/30 0.43 (.28–.63) 6.9 (.8–61.4)
Controlsb 1/10 0.10 (.03–.44)
Mascellino et al [11]
Cases 22/110 0.20 (.14–.29) 7.0 (3.1–15.8)
Controls 9/261 0.03 (.02–.06)
Simms et al [13]
Cases 17/140 0.12 (.08–.19) 18.7 (2.5–142.1)
Controlsb,c 1/136 0.01 (.00–.04)
Pooled estimate . . . . . . 9.2 (4.4–18.1)
Pooled adjusted . . . . . . 17.1 (7.9–34.0)
Abbreviations: CI, confidence interval; C. trachomatis, Chlamydia trachomatis.
a Binomial numerators and denominators.
b Confidence intervals are illustrative because there are insufficient numbers to assume
asymptotic normality.
c GP control group used.
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Germany [16], looked at 363 women with laparoscopically con-
ﬁrmed PID. C. trachomatis was found in the genital tract of 103
(28.4%), and in 55 (15.2%) it could be isolated from the cervix. In
23 (6.3%), C. trachomatis was isolated from both the cervix and
the fallopian tubes, while in 47 (12.9%), C. trachomatis was isolat-
ed from the fallopian tubes only. We use data from the study by
Erfurt et al to attempt to adjust for underascertainment of C. tra-
chomatis infection among the PID cases:
PEFð2Þa ¼
pa:ððOR=cÞ  1Þ
pa:ððOR=cÞ  1Þ þ 1 ;
where ψ is the proportion of all cases ofC. trachomatis infection in
womenwith PID in which the organism is isolated from the lower
genital tract. Details of how data from the study by Erfurt et al are
used to estimate ψ are given in Appendix 1.
PEF-3: Crude Estimate From Screening Trials and Age-Speciﬁc
Estimates of the Prevalence of C. trachomatis Infection
The PEF can be estimated using prospective studies. Observa-
tional studies will also provide estimates that are vulnerable to
signiﬁcant confounding. We therefore consider estimates from
randomized controlled trials (RCTs). Several RCTs designed to
estimate the effect of different types of screening have been per-
formed [17–19]. In 2, only the screened arm was tested at base-
line. However, in the POPI trial [17], one arm was screened and
treated immediately, while in the other arm samples were col-
lected but not tested until follow-up, 12 months later. Thus, the
relative risk (RR) of PID in women known to be C. trachomatis
positive at baseline (7 of 74 developed PID), compared with
women who are C. trachomatis positive but screened and treat-
ed and who are assumed to be C. trachomatis negative at base-
line (1 of 63 developed PID), can be estimated. Hence, the PEF
can be calculated using an estimate of the RR, based on a ran-
domized comparison:
PEFð3Þa ¼
paðRR  1Þ
paðRR  1Þ þ 1 :
The RR is the relative risk of developing PID in the exposed
versus unexposed group and approximates the incidence rate
ratio. The trial was performed in younger women (range, 16–
27 years; 89% were aged ≤24 years). Note that estimates for
age groups 25–34 years and 35–44 years should be treated
with caution as they extrapolate beyond the age range of the
POPI trial.
PEF-4: Crude Estimate From Screening Trials Adjusted for Treatment and
Age-Speciﬁc Prevalence of C. trachomatis Infection
The POPI protocol advised all women in the deferred screen-
ing arm to be independently tested. Of the C. trachomatis–
positive women in this arm, 43% were tested and treated during
follow-up. We assume that testing occurred randomly during fol-
low-up so that each of the 32 patients (74 × 43% = 32) who were
treated are at risk from the initial infection for a random time be-
tween 0 and 1 years. Therefore, the adjusted proportion of cases is
calculated as
v ¼ 42þ
P32
i¼1 Xi
74
Xi  Uniform(0,1),
where PEFð3Þa can thus be adjusted to allow for the effect of treat-
ment during follow-up, as follows:
PEFð4Þa ¼
paððRR=vÞ  1Þ
paððRR=vÞ  1Þ þ 1 :
PEF-5: Estimate-Based Synthesis of Screening Trials and Age-Speciﬁc
C. trachomatis Infection and PID Incidence
A ﬁnal method to estimate the PEF is the ratio of the incidence of
PID caused by C. trachomatis to the incidence of all-cause PID,
calculate as
PEFð5Þa ¼
ICTa R
CT.PID
IALLPIDa
;
where ICTa is the incidence of C. trachomatis, I
ALLPID
a is the inci-
dence of all-cause PID in England, and RCT.PID is the risk of
PID from a single C. trachomatis episode until the point of treat-
ment or clearance.
Estimates of C. trachomatis incidence are available from the
synthesis of incidence, prevalence, and duration studies previous-
ly cited (Table 3) [14].For the risk that C. trachomatis causes PID
(excess risk), we use an estimate of 17.1% (95% credible interval
[CrI], 5.6%–28.9%) taken from a recent synthesis of data from
3 RCTs of screening interventions [20].
There are 3 sources of routine data on PID incidence in
England: Hospital Episode Statistics (HES) [21], General Practice
Research Database (GPRD) [22], and routine KC-60 returns from
STI clinics [23] (Table 4). The 3 sources identify cases from differ-
ent care pathways, and there is an unknown degree of overlap
between them. We assume that the total of the STI, GPRD, and
Table 2. Estimates of the Prevalence of Chlamydia trachomatis Infection
Among Women Who Ever Had a Sex Partner
Age
C. trachomatis Prevalence, %,
Mean (95% CrI)
16–19 y 6.7 (4.5–9.5)
20–24 y 4.0 (2.9–5.3)
25–34 y 1.2 (0.8–1.6)
35–44 y 0.8 (0.5–1.3)
16–24 y 5.2 (3.8–6.9)
16–44 y 2.1 (1.6–2.7)
Data were obtained from a synthesis of data on C. trachomatis infection duration, incidence,
and prevalence from England, as reported by Price et al [14], and used in population excess
fraction (PEF) estimates 1–4.
Abbreviation: CrI, credible interval.
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HES data within each age group represents an upper bound for the
number of PID cases diagnosed in England each year. A mini-
mumwas formed by adding the number of cases identiﬁed at gen-
itourinary clinics to the largest of GPRD or HES cases [4]. A
comparatively direct estimate of PID incidence can be derived
from the control arm of the POPI trial [17] if we assume that
the trial sample is approximately representative of the general
female population of the same age, approximately 16–24 years.
In the unscreened arm, 23 cases of clinical PID were reported in
a sample of 1186 women aged 16–27 years followed up for 1 year.
Routine data only represent diagnosed “probable/deﬁnite” PID.
In the POPI trial, we assume that all symptomatic PID casesmeeting
the “probable/deﬁnite” criteria will be ascertained, including those
normally undiagnosed [4, 20]. To account for this, we identiﬁed a
single study providing estimates of the proportion of PID cases
that are symptomatic and diagnosed [5]. This is a cross-sectional
study of 36 women with TFI. Eleven reported a previous diagnosis
of PID, 21 reported a history of symptoms but no diagnosis, and
4 reported no history of symptoms or diagnosis.
We used these data to generate 2 independent estimates of PID
incidence in women. These estimates were found to be highly
consistent [4], so all of the data were jointly synthesized to gen-
erate the pooled estimates shown in Table 3.
Statistical Estimation
Estimation uses a Bayesian approach. Posterior medians and 95%
CrIs were obtained from the BayesianMarkov chainMonte Carlo
(MCMC) package WinBUGS, version 1.4.3 [24]. This method
ensures that all of the uncertainty in the data is fully propagated
into the estimates of PEF. Details of the prior distributions used
are given in Appendix 2. To assess goodness of ﬁt, we use the pos-
terior mean residual deviance, whose expected value approxi-
mates the number of data points under the assumption that
the model is true [25, 26]. Summary results are based on 2 chains
with 200 000 samples each after a 50 000 burn-in period. Conver-
gence was checked through visual inspection of trace and history
plots and the Brooks-Gelman-Rubin statistic [27], which demon-
strated convergence of all parameters within 1000 samples.
RESULTS
The 5 estimates of the PEF are shown in Table 5, and the full
marginal posterior distributions for the age group 16–24 years
are shown in Figure 1. Initial estimates of the PEF for women
aged 16–44 years ranged from 12% to 20%, but following adjust-
ment for biases, estimates ranged from 16% to 24%, showing a
fair degree of consistency, although 95% CrIs were wide. Our pre-
ferred estimate, based on RCT evidence and national estimates of
exposure and outcome, is 19.7% (95% CrI, 5.9%–38.1%).
In PEF-1 and PEF-2, the adjustment for underdetection of
C. trachomatis in case-controls studies, based on the study by Erfurt
et al, almost doubles the estimates of PEF within each age group
(from 13.7% to 23.7% in women aged 16–44 years). The dramatic
fall in PEF with age, from 49.3% in the group aged 16–19 years to
10.6% in the group aged 35–44 years, is a result of our assumption
that the OR is not related to age, whereas the prevalence of C. tra-
chomatis infection declines sharply (Table 2 and Figure 2).
PEF-3 and PEF-4 show a similar pattern with age. They are
similar to PEF-1 but lower than PEF-2, owing to the estimated
RR of 7.6 (95% CrI, 1.2–214.8) being lower than the estimated
OR (especially the adjusted OR) from the case-control studies.
However, the severe skew and very high variance of the posterior
distributions reduce their value.
The PEF-5 estimate, based on the ratio of C. trachomatis–related
PID to all-cause PID, is 19.7% (95% CrI, 5.9%–38.1%) in women
aged 16–44 years and 35.3% (95% CrI, 10.5%–68.5%) in women
aged 16–24 years and also shows a marked decline with age. This
decline, from 53.5% to 11.5%, is a reﬂection of the assumption of a
constant risk and the differing age proﬁles between C. trachomatis
infection and PID incidence (Figure 2).
DISCUSSION
We estimated the PEF of PID due to C. trachomatis in the United
Kingdom in the period just before screening was introduced, using
several different methods and data sources. We found reasonable
consistency between the adjusted estimates. It is reassuring that ad-
justed estimates based on case-control studies are fairly close to
Table 3. Estimated Incidence Rates of Chlamydia trachomatis Infection
and Pelvic Inflammatory Disease (PID) Among Women in England
Age
Incidence, Cases/100 Person-Years, Mean (95% CrI)
C. trachomatis Infection PID
16–19 y 6.5 (4.2–9.6) 2.1 (1.5–2.9)
20–24 y 3.9 (2.7–5.4) 2.8 (2.0–3.9)
25–34 y 1.1 (0.7–1.7) 1.9 (1.3–2.8)
35–44 y 0.8 (0.5–1.3) 1.3 (0.8–1.9)
16–24 y 5.0 (3.5–7.0) 2.5 (1.8–3.4)
16–44 y 2.1 (1.5–2.8) 1.8 (1.3–2.5)
Data on C. trachomatis infection are from Price et al [14], and data on PID are from Price et al [4].
Abbreviation: CrI, credible interval.
Table 4. Number of Incident Cases of Diagnosed Pelvic Inflammatory
Disease (PID) in England, 2002, by Data Source
Age
Hospital
Episode
Statistics
General Practice
Research
Databasea
Genitorurinary
Medicine
Clinicsb
Total
Female
Population
16–19 y 1233 5083 3212 1 199 600
20–24 y 3101 8842 4399 1 519 100
25–34 y 9756 14932 3919 3 502 100
35–44 y 10 526 9609 1388 3 795 600
a Definite and probable PID, as defined by French et al [22].
b Data by age not available for 2002, so we assumed that the age distribution for these data
were the same as in 2009.
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estimates derived in a very different way from the progression risk
from C. trachomatis to PID, C. trachomatis infection incidence,
and all-cause PID incidence, although this is tempered by the
high level of imprecision.
PEF drops by approximately 5-fold with age. In PEF-1–PEF-4,
this is a consequence of applying an assumed constant OR to a
prevalence that declines steeply with age. In PEF-5, the decline
is due to the assumed constant risk, the decline in C. trachomatis
infection incidence with age, the different age proﬁle of PID in the
routine data, and the assumption that the proportion of PID cases
that are undiagnosed is constant over age. Age-dependency
in PEF, if conﬁrmed, has a signiﬁcant impact on the public
health importance of C. trachomatis, as the majority of ectopic
pregnancies and TFI cases occur in older women. Although C.
trachomatis infections in younger women may have a key role
in reproductive health problems that emerge many years later,
these results focus attention on the distinctly different age proﬁles
of C. trachomatis and PID. If the risk proﬁle changes with age, this
may cause inconsistency in estimates of PEF between prospective
and retrospective estimates. Studies following up women with C.
trachomatis theoretically sample the (younger) C. trachomatis–in-
fected population, whereas retrospective studies randomly sample
the (older) PID population.
There are limitations to our analyses. The diagnosis of PID is
imprecise, with no gold standard diagnostic test and changing
criteria for diagnosing PID [2, 3, 6], with healthcare providers
Table 5. Alternative Estimates of the Population Excess Fraction (PEF) From Each Model
Age
PEFð1Þa : Case-Control Data
and C. trachomatis
Prevalencea
PEFð2Þa : Adjusted
Case-Control Data and
C. trachomatis Prevalenceb
PEFð3Þa : Screening Trials
and C. trachomatis
Prevalencec
PEFð4Þa : Adjusted Screening
Trials and C. trachomatis
Prevalenced
PEFð5Þa : Screening Trials,
C. trachomatis and PID
Incidencee
16–19 y 33.1 (16.9–54.8) 49.3 (29.4–70.3) 30.1 (1.1–93.4) 36.4 (3.1–94.8) 53.5 (15.6–100)
20–24 y 22.8 (11.1–41.4) 36.8 (20.4–58.0) 20.6 (0.7–89.5) 25.5 (1.9–92.6) 24.3 (7.2–47.6)
25–34 y 7.8 (3.4–17.2) 14.4 (6.7–28.8) 6.9 (0.2–71.1) 9.0 (0.6–76.0) 10.6 (2.9–21.2)
35–44 y 5.7 (2.3–13.5) 10.6 (4.6–23.3) 5.0 (0.1–63.7) 6.5 (0.4–69.2) 11.5 (3.0–25.7)
16–24 y 27.8 (14.0–47.9) 43.1 (25.0–64.2) 25.2 (0.9–91.6) 30.8 (2.5–93.4) 35.3 (10.5–68.5)
25–44 y 6.8 (2.9–15.1) 12.5 (5.8–25.8) 6.0 (0.2–67.7) 7.8 (0.5–72.9) 10.6 (3.0–21.9)
16–44 y 13.7 (6.4–27.1) 23.7 (12.3–42.0) 12.2 (0.4–81.8) 15.5 (1.0–85.3) 19.7 (5.9–38.1)
Data are posterior medians (95% credible intervals).
Abbreviations: C. trachomatis, Chlamydia trachomatis; PID, pelvic inflammatory disease.
a Estimates are based on 3 case-control studies.
b Estimates are based on 3 case-control studies, but the odds ratio was adjusted by data from the study by Erfurt et al [16] (see text).
c Median PEF derived from the risk in the C. trachomatis–positive group relative to that in the C. trachomatis–positive and treated group in the POPI trial.
d Median PEF derived from the risk in the C. trachomatis–positive group relative to that in the C. trachomatis–positive and treated group in the POPI trial, with adjustment for independent testing
in the referral group.
e Data are the ratio of the C. trachomatis–related PID incidence, estimated as the product of C. trachomatis incidence [11] and risk of progression from C. trachomatis infection to PID [20], to the
all-cause PID incidence (Table 3) [4].
Figure 1. Evidence consistency plot showing the posterior densities for the 5 estimated population excess fractions (PEFs) in women aged 16–24 years. Posterior distri-
butions are based on 950 000 samples in bins of size 0.005 with a 3-bin moving average smoother applied. See Appendix 2 for further details. Abbreviations: C. trachomatis,
Chlamydia trachomatis; PID, pelvic inflammatory disease.
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now being advised to maintain a low threshold for diagnosis [3].
Diagnosis of PID was usually obtained retrospectively, often by
review of notes. Thus, there is also likely to be inconsistency in
the use of and application of clinical criteria for the diagnosis
of PID between the different studies. PEF-1 and PEF-2 use
pooled ORs estimated from case-control studies. Owing to the
likelihood of confounding, there is almost certainly an upward
bias, as the risk factors for C. trachomatis infection are similar
to the risk factors for other causes of PID, and the relevance of
these studies to the United Kingdom is uncertain. PEF-3–PEF-5
are advantaged by being based on randomized comparisons re-
ducing the risk of confounding. Finally, the decrease in these
PEFs with age is in part due to our unavoidable assumption
that neither the probability that PID is diagnosed nor the risk
of PID following C. trachomatis infection, either directly in
PEF-5 or through the assumptions of constant ORs and RRs in
PEF-1–PEF-4, are age dependent. The rate of PID development
can vary with age and past number of diagnosed C. trachomatis
episodes [28]. But this does not inform whether risks from an in-
dividual (often undiagnosed)C. trachomatis infection vary. How-
ever, the degree of variation with age, by a factor of 4–6 between
ages 16–19 years and age 35–44 years, is so great it would require
extreme trends in one or both of those quantities to reverse it.
Our preferred estimate is PEF-5—19.7% (95% CrI, 5.9%–
38.1%)—because it uses a synthesis of randomized evidence
that accounted for clearance and reinfection to estimate risk in
conjunction with population-level estimates of exposure and dis-
ease incidence. While there are good scientiﬁc reasons why we ex-
pect this to be the most reliable estimate, it is a post hoc decision.
Our estimates for the groups aged 16–44 years are lower than
the estimate of 30% by Paavonen et al [7],mentioned previously
from uncontrolled studies. Such studies likely overestimate the
PEF as some of this exposure is likely coincidental. However, it
has been argued [15] that this must also underestimate the cur-
rent role of C. trachomatis infection, as gonorrhea was a com-
mon cause of PID during the period when many of these studies
were undertaken, and it is generally agreed that gonorrhea is now
far less common, particularly in Europe. Simms and Stephenson
[8] found a range for the C. trachomatis infection prevalence of
12%–61% in the upper genital tract of women with laparoscopi-
cally proven PID, with considerable variation across countries.
The largest United Kingdom study, conducted between 1989
and 1993, reported 39% [29]. In another United Kingdom
study, conducted from 2000 to 2002, 42 of 140 salpingitis cases
(30%) had evidence of exposure to C. trachomatis. We excluded
these studies as they lack a control group, and none reported ﬁnd-
ings by age. However, if a control group had identiﬁed C. tracho-
matis in around 3% of women (roughly the prevalence in a
population with the age distribution of PID cases), then an esti-
mated PEF would be similar to our estimates. Such studies would
typically require a similar adjustment to that described in PEF-2.
Our estimated adjustment factor from the study by Erfurt
et al, 1.6, is close to an estimate by Taylor-Robinson et al,
who observed that infection at the cervix appears to underesti-
mate the role of C. trachomatis in PID-related reproductive
damage by a similar amount [30]. This was based on the obser-
vation that, of the 22 women with acute salpingitis diagnosed
on the basis of laparoscopy ﬁndings, 10 had C. trachomatis de-
tected in cervical specimens, and an additional 6 had high-titer
serum C. trachomatis immunoglobulin G antibody [30].
The focus of PID prevention strategies has centered on STIs,
particularly C. trachomatis infection but also Neisseria gonor-
rhoeae infection and more recentlyMycoplasma genitalium infec-
tion [3, 31, 32].However, in the United Kingdom, gonorrhea is an
uncommon cause [33], and an unknown but probably small pro-
portion is caused byM. genitalium [3, 31, 32, 34]. If C. trachomatis
Figure 2. Posterior density plot for population excess fraction estimate 5 (PEF-5) by age group. Posterior distributions are based on 950 000 samples in bins of size 0.005 with
a 3-bin moving average smoother applied. See Appendix 2 for further details. Abbreviations: C. trachomatis, Chlamydia trachomatis; PID, pelvic inflammatory disease.
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is responsible for 20% of PID cases, then non-STI causes deserve
more attention in PID prevention. These include microorganisms
associated with bacterial vaginosis, which are commonly present
in women with PID, and respiratory and enteric pathogens that
have colonized the lower genital [3, 32, 35, 36]. Sexual exposure
increases the risk of bacterial vaginosis [3, 35, 37], and sexual ac-
tivity likely heightens the risk of ascending infection due to all
pathogens. It is unknown whether the proportion of PID cases
caused by non-STI microorganisms present in the vaginal micro-
biome [35] increases with age as the C. trachomatis PEF decreases,
but this is possible [35, 36]. Currently, young age, multiple sex
partners, and new partners, risk factors for STIs, are considered
important risk factors when considering a diagnosis of PID in
women who present with lower abdominal pain [3, 31, 38]. If
older women are at increased risk of PID from non–STI-associat-
ed bacteria as the risk of C. trachomatis infection decreases, this
needs to be recognized in clinical management guidelines for di-
agnosis and therapy [3, 31].
Future studies of the relationship between C. trachomatis and
PID should focus more on the relationship between risk and age.
Furthermore, age is a proxy measure for underlying factors such as
cumulative incidence and immunological status. Serological studies
using up-to-date assays in conjunction with other data sources may
shed light on these more complex issues. Further work establishing
the degree of overlap between cases identiﬁed in different routine
data sources is required. Finally, more focus should be placed on
investigation of the role of non-STI vaginal microbiota in PID.
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APPENDIX 1
LITERATURE SEARCH: IDENTIFICATION OF
CASE-CONTROL STUDIES OF C. TRACHOMATIS
PREVALENCE IN PID CASES AND CONTROLS
We searched for studies using current C. trachomatis infection
as a marker of C. trachomatis exposure. Strictly speaking, in a
synthesis focusing on prevalence and sequelae of C. trachomatis
in the United Kingdom, only contemporary United Kingdom
data should be used. We have, nevertheless, used data from Eu-
rope because the epidemiology of STIs is generally similar in
Western European countries. Studies from North America
have been excluded because gonorrhea has tended to have a
more important role in the etiology of PID in North America
than in the United Kingdom [39–41].We also excluded studies
published before the 1990s. Our literature identiﬁcation process
is described in more detail elsewhere [4] and identiﬁed 3 studies
shown in Table 1.
META-ANALYSIS MODEL
The 6 data points are used to estimate 4 parameters: 3 study-speciﬁc
“baselines”; the log odds in the control groups, μS, with s indexing
study; and 1 ﬁxed-effect log OR, β.Using a standard logistic regres-
sion model, with 0 for controls and 1 for PID cases,
logitðlS;0Þ ¼ ms
logitðlS;1Þ ¼ ms þ b
the OR can be recovered via the following equation: OR ¼ expðbÞ.
For PEF-2, data from the study by Hoyme et al [16] are used
to place an informative prior on ψ, deﬁned as the proportion of
all cases of C. trachomatis infection in women with PID in
which the organism is isolated from the lower genital tract,
such that c  Beta(56,47).
APPENDIX 2
PRIOR DISTRIBUTIONS
For the incidence rate and prevalence of chlamydial infection, a
Multivariate Normal approximation (on the log and logit scales,
respectively) to the full joint posterior distribution from the ar-
ticle by Price et al [14] is used. For PID incidence, the age-group
speciﬁc rates of undiagnosed PID are given exponential(0.0001)
priors. Exponential(0.01) priors give identical answers. The
proportion of PIDs that are undiagnosed and the proportion
of undiagnosed PIDs that are silent are given Beta(1,1) priors.
The OR in PEFs 1 and 2 is estimated using a logistic regres-
sion model with Normal(0,10 000) priors on the baseline and
treatment parameters in the linear predictor. This is a fairly
standard uninformative prior for this type of model. Assuming
Normal(0,100) priors alters the (unadjusted) estimate from 9.2
(4.4,18.1) to 9.1 (4.3,17.7). The adjustment factor from the
study by Erfurt et al is also introduced as a Beta distribution de-
rived directly from the data. The RR estimate for PEFs 3 and 4 is
calculated as the simple ratio of the risks in each arm, which
are given informative Beta prior distributions derived directly
from the data. The adjustment factor for the POPI trial (used
in PEF-4) is a Uniform distribution bounded between limits de-
ﬁned by the observed data. For PEF-5, the risk of PID due to a
C. trachomatis infection is input as an informative Normal ap-
proximation to the posterior distribution estimated by Price
et al [20].
FIGURE-SMOOTHING ALGORITHM
Figure 1 shows density plots of the marginal posterior distribu-
tions for PEF-1–PEF-5. The 0-1 PEF proportion is split into
n = 200 bins of size 0.005. For each PEF, the proportion of
950 000 raw MCMC draws falling into each bin yn is recorded.
x = 200 points are calculated using a 3 bin smoother such that
x1 ¼ y1; x2 ¼
P2
n¼1 ðyn=2Þ , and xn ¼
Pn
n2 ðyn=3Þ and for
n = 3–200. The points x are used to plot the line graphs. The
same smoother is used in Figure 2.
Figures 1 and 2 only show the posterior densities for the region
0 to 1. However, the PEFs are not bounded strictly within this
region. PEF-1–PEF-4 are naturally bounded at 1 by the equa-
tions. This is not the case for PEF-5. Values of >1 were only sam-
pled for PEF-5 in the 16–19-year age group, and these are not
shown in the ﬁgure.
None of the PEFs are explicitly bounded at 0, and negative
values were sampled for PEF-3 and PEF-4, as the distribution
of the estimated RR does not rule out a protective effect from
chlamydial infection. However, due to the extreme implausibil-
ity of this and difﬁculties with interpretation of negative PEFs
calculated in this way, these are not displayed.
Note that, as we report posterior medians, the central esti-
mates of PEF are unaffected by this. If upper or lower CrIs lie
outside the range 0 to 1, these have been set to 0 or 1, respec-
tively. Where necessary, the densities in Figures 1 and 2 have
been rescaled slightly to integrate to 1 within the 0 and 1
boundaries.
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